论文部分内容阅读
目的探讨VEGFR-3和CD31在前列腺癌组织的表达及与术后生存率关系。方法采用EnVisionTM免疫组织化学法,检测43例前列腺癌癌组织和10例癌周组织VEGFR-3和CD31表达,采用Weidner最高血管密度计数法,计数癌组织中阳性淋巴管数(MLC)和微血管密度(MVD);结合临床资料分析VEGFR-3和CD31与前列腺癌术后生存率的关系。结果前列腺癌组织中MLC和MVD分别为(8.90±2.28)mm2和(72.46±10.32)mm2,显著高于癌周组织的(4.03±2.16)mm2和(30.91±5.27)mm2,差异有统计学意义(P<0.01)。术后2年内死亡者的MLC和MVD分别为(10.52±1.83)mm2与(92.30±10.19)mm2;2~5年死亡者分别为(8.59±2.73)mm2和(85.87±12.95)mm2;>5年死亡者分别为(6.67±1.23)mm2与(61.19±10.50)mm2,差异有统计学意义(P<0.05)。TNM分期T1、T2期者MLC和MVD分别(7.46±1.13)mm2与(65.10±12.84)mm2,T3、T4期者分别为(9.25±2.51)mm2与(83.78±10.83)mm2,差异有统计学意义(P<0.05)。无骨转移者(72.09%)MLC和MVD分别为(6.67±1.23)mm2与(61.19±10.50)mm2;有骨转移者(27.91%)分别为(10.37±1.06)mm2与(97.74±14.62)mm2,差异有统计学意义(P<0.05)。结论VEGFR-3和CD31高表达提示前列腺癌组织有新淋巴管和血管生成,VEGFR-3和CD31检测可用于判断前列腺癌患者的生存质量。
Objective To investigate the expression of VEGFR-3 and CD31 in prostate cancer and its relationship with postoperative survival. Methods EnVisionTM immunohistochemistry was used to detect the expression of VEGFR-3 and CD31 in 43 cases of prostate cancer and 10 cases of peritumoral tissue. The Weidner’s highest vascular density counting method was used to count the number of positive lymphatic vessels (MLC) and microvessel density (MVD). The clinical data were used to analyze the relationship between VEGFR-3 and CD31 and postoperative survival rate of prostate cancer. Results The MLC and MVD in prostate cancer tissues were (8.90 ± 2.28) mm2 and (72.46 ± 10.32) mm2, respectively, which were significantly higher than those in the peritumoral tissues (4.03 ± 2.16 mm2 and (30.91 ± 5.27) mm2, respectively) (P <0.01). The MLC and MVD of those who died within 2 years after operation were (10.52 ± 1.83) mm2 and (92.30 ± 10.19) mm2, respectively; those who died within 2 to 5 years were (8.59 ± 2.73) mm2 and (85.87 ± 12.95) mm2, respectively; The annual deaths were (6.67 ± 1.23) mm2 and (61.19 ± 10.50) mm2, respectively, the difference was statistically significant (P <0.05). (7.46 ± 1.13) mm2 and (65.10 ± 12.84) mm2, T3 and T4 in TNM stage T1 and T2 were (9.25 ± 2.51) mm2 and (83.78 ± 10.83) mm2 respectively, the difference was statistically significant Significance (P <0.05). MLC and MVD were (6.67 ± 1.23) mm2 and (61.19 ± 10.50) mm2 respectively in those without bone metastasis (27.09%) and (10.37 ± 1.06) mm2 and (97.74 ± 14.62) mm2 respectively , The difference was statistically significant (P <0.05). Conclusion The high expressions of VEGFR-3 and CD31 suggest that lymphangiogenesis and angiogenesis may be involved in prostate cancer. The detection of VEGFR-3 and CD31 may be useful in judging the quality of life of patients with prostate cancer.